Limitations, agreements, and source contact

Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma · Source last updated 2020-03-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

false

point Of Contact

email

bhauns@pcyc.com

organization

Pharmacyclics Switzerland GmbH

phone

+41 52 556 0800

title

Dr. Bernhard Hauns, Medical Monitor

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice